You can also search for this author in After 6 months, PPG levels were significantly decreased only in the repaglinide group (P < 0.05 vs baseline); at 12 months, however, PPG levels were significantly reduced from baseline in both groups (P < 0.01 repaglinide, P < 0.05 glimepiride).

2005, 68 (2): 89-95. Diabetes Care.

2006 May;28(5):679-88. doi: 10.1016/j.clinthera.2006.05.012.Derosa G, Salvadeo SA, D'Angelo A, Ferrari I, Mereu R, Palumbo I, Maffioli P, Randazzo S, Cicero AF.Curr Med Res Opin. 10.1161/ATVBAHA.107.157164.Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. 2010, 362 (16): 1477-1490.Kawamori R, Kaku K, Hanafusa T, Kashiwara D, Kageyama S, Hotta N: Efficacy and safety of repaglinide vs nateglinide for treatment of Japanese patients with type 2 diabetes mellitus. Eur Heart J. Actually, we confirmed that the patients’ physical conditions and lifestyles didn’t change every 4 week. MAGE, the standard deviation (SD) of blood glucose level, mean blood glucose level (mean BG), percent of hours under 3.9 mmol/L of serum glucose in 24 hours and percent of hours over 10.0 mmol/L of serum glucose in 24 hours were calculated from the glucose curve on day 3 in order to exclude the influence of the meals on the first day of CGM.Data in the tables and figures were expressed as mean ± SD, with the exception of CGM (mean ± SEM). 2011, 124 (2): 172-176.Stephens JW, Bodvarsdottir TB, Wareham K, Prior SL, Bracken RM, Lowe GD, Rumley A, Dunseath G, Luzio S, Deacon CF, Holst JJ, Bain SC: Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus. Although the glucose control parameters were not significantly different between glimepiride and repaglinide, the mean amplitude of glycemic excursions measured by continuous glucose monitoring was significantly reduced by changing treatment from glimepiride to repaglinide. 2014 Aug;31(8):611-21. doi: 10.1007/s40266-014-0192-2.Nakamura I, Oyama J, Komoda H, Shiraki A, Sakamoto Y, Taguchi I, Hiwatashi A, Komatsu A, Takeuchi M, Yamagishi S, Inoue T, Node K.Cardiovasc Diabetol. 2013 Oct 31;9(5):936-43. doi: 10.5114/aoms.2013.34991. 2011, 94 (2): 199-206. Acta Diabetol. © 2020 BioMed Central Ltd unless otherwise stated.

2008, 28 (7): 1385-1391. MA, TS, MT, MF, NN contributed to discussion, GH and MK reviewed/edited manuscript. Diabetes Metab. Diabetes. All the patients were Japanese with a mean age of 68.0 ± 6.5 years and HbA1c of 7.0 ± 0.2% (range 6.7 ~ 7.2%).

The other baseline data are shown in Table After 12 weeks of treatment with repaglinide, there were no significant changes in body weight or BMI (Table The 24-h blood glucose profiles in day 3 of CGM are shown in Figure This study on patients with type 2 diabetes on glimepiride showed that a change in treatment to repaglinide resulted in a significant decrease in both inflammatory (PAI-1, hs-CRP) and oxidative stress markers (u-8-OHdG), despite glucose control parameters (HbA1c, GA, and mean BG) remaining unchanged. 10.1111/j.1463-1326.2006.00638.x.Shramm TK, Gislason GH, Vaag A, Rasumussen JN, Folke F, Hansen ML, Fosbol EL, Kober L, Norgaard ML, Madsen M, Hansen PR, Torp-Pedersen C: Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. 2000, 342: 836-843.